12/26/2023 0 Comments Schering bayer![]() ![]() Bioz Stars score: 86/100, based on 1 PubMed citations. Employing the legally defined squeeze-out procedure, it is intended that the shares owned by minority stockholders be transferred to the main stockholder, Bayer Schering GmbH, a wholly owned subsidiary of Bayer AG, in return for adequate cash compensation. Genzyme bayer schering Bayer Schering, supplied by Genzyme, used in various techniques. The resolution necessary for a squeeze-out is expected to be passed at an Extraordinary Stockholders' Meeting of Bayer Schering Pharma AG to be held in Berlin on January 17, 2007. Now we are focusing on the next steps, particularly the squeeze-out process and realizing the planned synergies."īayer Schering Pharma AG, headquartered in Berlin, is to be managed together with Bayer's current pharmaceutical business as a division of the Bayer HealthCare subgroup. The appointment of highly qualified people to important positions, particularly in research and development, is largely complete, and we were able to fill these positions equitably with employees from both companies. "We are continuing to make good headway with the integration process. "We are pleased that Schering now belongs to the Bayer Group in name as well, and that this is visible to the world," said Bayer AG Management Board Chairman Werner Wenning. The new logo has already been mounted on Bayer Schering Pharma's headquarters building in Berlin. Following the entry of the domination and profit and loss transfer agreement in the commercial register on October 27, 2006, this means another important condition for combining Bayer's and Schering's pharmaceutical activities has been fulfilled. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.Germany-based pharmaceutical company Schering has now been officially renamed "Bayer Schering Pharma AG." The necessary entry in the commercial register took effect on December 29, 2006. The company assumes no duty to update the information to reflect subsequent developments. The information contained in this website was current as of the date presented. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended Decemand the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (No Duty to Update ![]() The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Risks and uncertainties include but are not limited to, general industry conditions and competition general economic factors, including interest rate and currency exchange rate fluctuations the impact of the global outbreak of novel coronavirus disease (COVID-19) the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally global trends toward health care cost containment technological advances, new products and patents attained by competitors challenges inherent in new product development, including obtaining regulatory approval the company’s ability to accurately predict future market conditions manufacturing difficulties or delays financial instability of international economies and sovereign risk dependence on the effectiveness of the company’s patents and other protections for innovative products and the exposure to litigation, including patent litigation, and/or regulatory actions. Schering Profile and History File:Bild-Cecil Foto-Exkursion Berlin 2008 Bayer Schering Pharma.jpgthumbHeadquarters of Schering AG, now Bayer HealthCare Pharmaceuticals, in Berlin Schering AG was a research-centered German multinational pharmaceutical company headquartered in Wedding, Berlin, which operated as an independent company from 1851 to 2006. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. Private Securities Litigation Reform Act of 1995. This website of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |